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ABSTRACT 
Analysis of the Mouse Immunome Reactive against Schistosoma mansoni Egg Antigens. (May 
2015) 
 
Annalisa Erder 
Department of Nutritional Sciences 
Texas A&M University 
 
Research Advisor: Dr. Barbara Doughty 
Department of Biology 
 
Schistosomiasis is a waterborne parasitic infection affecting more than two hundred million 
people in the tropical and subtropical regions of the world. Currently, the disease is treated with 
the drug Praziquantel, but reinfection is common. If an anti-pathology vaccine were created, the 
rate of infection and reinfection of schistosomiasis would be significantly reduced. Humans with 
asymptomatic intestinal schistosomiasis and mice with moderate splenomegaly syndrome (MSS) 
share certain cross-reactive idiotypes (CRI), which are absent in the anti-egg antigen specific 
antibody responses of symptomatic hepatosplenic patients and mice with hypersplenomegaly 
syndrome (HSS). We hypothesize that CRI unique to MSS down-regulate the progress of the 
disease, while CRI unique to HSS may be pro-inflammatory. Therefore, identifying the proteins 
unique to each disease state could be used to produce a vaccine. CBA/J male mice with twenty-
week infections develop the full chronic disease as seen in humans. Predictably 10 - 20% of 
infected mice will develop severe HSS. In order to identify all soluble proteins from schistosome 
egg antigens (SEA), proteins were separated based on size, pH, and pI by two-dimensional 
electrophoresis. Then unique antigen reactivity of the CRI was detected by Western blotting. To 
identify the antigens, the stains were compared to an SEA Proteomic map generated in The 
Center for Biodiscovery and Proteomics, University of Wellington, New Zealand, where protein 
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analysis was completed via Matrix-Assisted Laser Desorption/Ionization – Time of Flight 
(MADLI-TOF) mass spectrometry. Results indicate that, while an estimate of thirty antigens are 
represented in both disease states, there are a few differences. Three antigens have been 
identified as unique to MSS: Calreticulin precursor, Calreticulin, and SJCHGCO1881 protein. 
Two antigens unique to HSS are Enolase (2phosphoglycerate dehydratase) and one unidentified 
protein. Future research would investigate the effectiveness of these antigens as anti-pathology 
vaccines, perhaps by using those only unique to MSS to promote down-regulation. 
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4	  
	  
ACKNOWLEDGEMENTS 
Many thanks go to Dr. Barbara Doughty for mentoring me in her laboratory and to all who have 
supported my research and education. 
  
5	  
	  
NOMENCLATURE 
 
2DE  two-dimensional electrophoresis  
CRI  cross-reactive idiotypes  
gi   genInfo identifier 
HSS  hypersplenomegaly syndrome 
Id  idiotype 
IgG  immunoglobulin 
IL-10  interleukin-10 
IPG  immobilized pH gradient 
MQ  Milli-Q water 
MSS  moderate splenomegaly syndrome  
PBST  phosphate buffered saline/tween 
pI  isolectric point 
SEA  soluble egg antigen 
TNF-a  tumor necrosis factor alpha 
 
  
6	  
	  
CHAPTER I 
INTRODUCTION 
 
Overview of Schistosomiasis 
More than 200 million people worldwide suffer from the disease schistosomiasis, which is 
caused by infection from the trematode fluke known as a schistosome (“Schistosomiasis,” 2012). 
Three species of the fluke cause schistosomiasis: Schistosoma (S.) mansoni, S. hematobium and 
S. japonicum (Coligan, 1991). The disease is concentrated near regions with bodies of 
freshwater. For example, cases of S. mansoni are typically reported in sub-Saharan Africa and 
South America. There is also a low risk for contracting infection via S. mansoni in the 
Caribbean. S. hematobium is more common in North Africa, Egypt and throughout sub-Saharan 
Africa, and in the Middle East. S. japonicum causes most infections in Southeast Asia, 
Indonesia, and China. The people in these areas are most susceptible to the disease because of 
their poor or nonexistent sanitation systems (“Schistosomiasis,” 2012).  
 
FIG. 1: Distribution of Schistosomiasis, Worldwide, 2009 (World Health Organization) 
7	  
	  
 
This research will focus on S. mansoni, which has a complex life cycle involving a snail 
intermediate and a human host. In humans, the adult male and female worms live in copula in the 
mesenteric veins of the small intestine, continuously releasing eggs. Some of the eggs break 
through the host’s intestinal wall and enter the intestinal lumen to be excreted with feces, while 
other eggs are trapped in the liver and elicit a range of immune responses (“Schistosomiasis 
FAQs,” 2012).  
There are two main disease states of schistosomiasis. In most patients, the disease becomes 
chronic without major pathology (Mbow et al., 2012). This is known as “asymptomatic 
schistosomiasis,” which results in moderate hepatic fibrosis. It is possible to live for many years 
while suffering from this disease state of schistosomiasis. However, in some patients (~10%), the 
infection leads to “symptomatic schistosomiasis” as a result of eggs entrapped in the precapillary 
sinusoids of the liver, eliciting severe hepatic granuloma formation and fibrosis that most often 
results in death (“Schistosomiasis FAQs,” 2012). The granuloma is composed of primarily 
macrophages, T-lymphocytes, and fibroblasts, and it forms to protect the body from the soluble 
egg antigens (SEAs) that the egg releases, which are toxic to the liver (“General Pathology 
Associated with Schistosome Infections,” 2010). From this information, it has been found that 
those suffering from asymptomatic schistosomiasis do not produce the same anti-SEA antibodies 
as those suffering from symptomatic schistosomiasis, discussed in depth later. Those suffering 
from symptomatic schistosomiasis react to the parasite with a protective inflammatory response, 
whereas those suffering from asymptomatic schistosomiasis produce a down-regulatory 
response. The down-regulatory response results in a slower fibrosis of vital organs, resulting in a 
longer lifespan. The goal of this research is to identify any discrepancies in antibodies produced 
in each disease state. By doing so, it may be possible to produce a vaccine that promotes the 
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down-regulatory response in the infected person, rather than promoting the lethal inflammatory 
response.    
Similar percentages of these disease states have been reported in a CBA/J mouse model of 
schistosomiasis. Therefore, the asymptomatic form of schistosomiasis, or “moderate 
splenomegaly syndrome” (MSS), and the symptomatic form, or “hepatic splenomegaly 
syndrome” (HSS), are comparable to the human disease states and serve as a realistic model for 
laboratory experiments. 
 
Life Cycle of S. mansoni 
 
 
FIG. 2: Life cycle of S. mansoni (“Schistosomiasis: Biology,” 2012) 
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The lifecycle of S. mansoni begins when S. mansoni eggs hatch to release miricidia, the term for 
the ciliated larvae of parasitic flukes, into a water source. The miricidia swim and search for an 
intermediate host, typically a snail ("Schistosomiasis: Disease," 2012). The species of snail 
Biomphalaria glabrata commonly hosts S. mansoni ("Life Cycle of S. mansoni - Host Snails of 
Human Schistosomes," 2010). Once the miricidia have penetrated the snail, a series of asexual 
developments begin. Namely, two generations of sporocysts develop: a mother sporocyst and a 
daughter sporocyst. The daughter sporocyst produces cercariae, the term for the free-swimming 
infectious larvae of parasitic flukes ("Life Cycle - Host Snails," 2010). The cercariae have 
characteristic forked tails, allowing them to survive in water for about forty-eight hours while 
they search for a vertebrate host ("Schistosomiasis: Disease," 2012).  
 
FIG. 3: Anatomy of the cercariae of S. mansoni (“Life Cycle - The Schistosome Cercaria,” 2010) 
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Once the vertebrate host is located, the cercaria attaches to and penetrates the host’s skin by 
secreting proteolytic enzymes from glands in its head (“Life Cycle - The Schistosome Cercaria,” 
2010). It takes the cercaria roughly thirty minutes to penetrate the epidermis, but it can take up to 
a day for it to completely penetrate the basal lamina, and an additional ten hours to completely 
penetrate the dermis. (“Life Cycle - Skin Penetration,” 2010). After penetrating all of the dermal 
layers, the parasite enters the bloodstream.  
 
FIG. 4: Cercaria Penetration of the Epidermis (“Life Cycle of S. mansoni - Skin Penetration & Infection,” 2010) 
 
Immediately after dermal penetration, the cercaria loses its tail to enter its next stage of life as a 
schistosomulum (“Life Cycle - The Schistosome Cercaria,” 2010). As a schistosomulum, the 
parasite begins to circulate in the body through the veins, passing through the pulmonary artery 
to the lungs before reaching the liver via the hepatic portal vein and entering its adult stage. 
While in the lungs, the schistosome undergoes an intermediate growth stage by consuming 
plasma, and it only fully matures in the liver. Here, the mature male schistosome mates with a 
mature female, and the schistosomes lay eggs for approximately a month at a time. (“Life Cycle 
– Schistosomula,” 2010). At this point, the eggs may be excreted in feces, starting the life cycle 
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over again, or they will become lodged in the liver and spleen, causing the granuloma formation 
and fibrosis characteristically symptomatic of the disease. 
 
Symptoms and Diagnosis of Schistosomiasis 
Humans do not typically show symptoms of schistosomiasis until the schistosomes burrow into 
the blood vessels and mature into adults. At this point, a skin rash may develop and persistently 
worsen. Between one to two months of infection, the human host may exhibit flu-like symptoms 
including “fever, chills, cough, and muscle aches” ("Schistosomiasis: Disease," 2012). There is 
also a small chance that schistosome eggs may travel to the brain or spinal cord. This causes 
seizures, paralysis, and spinal cord inflammation. ("Schistosomiasis: Disease," 2012). A blood 
test is necessary to diagnose schistosomiasis. Stool samples can also be collected to examine for 
eggs; however, because eggs are produced cyclically, there is a chance that eggs will not be 
found in the feces. The most accurate way to diagnose schistosomiasis is with the blood test. 
("Schistosomiasis: Disease," 2012) 
 
Treatment of Schistosomiasis  
Typically, administration of the drug Praziquantel adequately treats schistosomiasis by killing 
the parasite. However, the only way to truly prevent schistosomiasis is to properly clean and 
maintain the population’s water supply as well as eliminate the intermediate host snail (USAID). 
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Mouse Model of Schistosomiasis  
The development of HSS in CBA/J male mice with twenty-week infections correlates with 
elevations in tumor necrosis factor alpha (TNF-a) liver mRNA and collagen deposition and with 
lower levels of interleukin-10 (IL-10), an anti-inflammatory cytokine (Sadler et al., 2003). In 
addition, SEA-specific antibodies present in the sera of MSS mice display a distinct set of SEA 
specific antibody specificities known as idiotypes (Id) compared to those from sera of infected 
mice with HSS (Ludolf et al., 2014).  The Id preparations from the sera of MSS mice (MSS Id) 
stimulate T cell proliferation and the production of distinctive cytokine patterns by spleen cells 
from infected mice while Id prepared from sera of HSS animals (HSS Id) is not stimulatory 
(Mbow et al., 2012).  These differences parallel those observed in human patients with 
asymptomatic and symptomatic forms of the disease. The most exciting aspect of these parallels 
is the observation that humans with asymptomatic schistosomiasis and mice with MSS share 
certain idiotypes, as demonstrated by the cross-reactivity of rabbit antisera specific for 
asymptomatic patients’ Id with MSS Id. In contrast, these cross-reactive idiotypes (CRI) are 
absent in the anti-egg antigen specific antibody responses of both mice with HSS and 
symptomatic schistosomiasis patients. In the CBA/J chronic infection model, CRI is present in 
the sera of mice that develop MSS by six weeks after infection whereas mice that develop HSS 
chronic pathology or die before twenty weeks of infection never produce CRI. In summary, MSS 
results in immunosuppressive CRI that prevent severe fibrosis of the liver and spleen, and these 
CRI are absent in HSS. Identifying the CRI would allow them to be used in vaccinations to 
promote the down-regulatory response in those suffering from schistosomiasis.    
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CHAPTER II 
MATERIALS AND METHODS 
 
Overview of Procedure 
There are two main steps involved in the protein analysis procedure: two-dimensional 
electrophoresis (2DE) and western blot. 2DE separates the SEA based on pH, isoelectric point 
(pI), and size. Of four gels, one gel is stained as a reference and the other three are transferred to 
nitrocellulose for Western blot analysis. Staining the gel allows all the separated antigens to 
stain, while a Western blot allows only the antigens that reacted to the specific antibodies to 
stain. 
 
The following procedures have been adapted from Current Protocols in Immunology.  
Protein Extraction of soluble egg antigens 
Frozen S. mansoni eggs were obtained from BRMI (Biomedical Research Institute) in Rockville, 
Maryland and stored at -80° C until use.  Eggs were washed five times in sterile phosphate 
buffered saline, then resuspended in Lysis Buffer (LB) pH 8.4 (30 mM TrisHCL pH 8.8, 2M 
thiourea, 7M urea, 4% (w/v) CHAPS) and homogenized in a motor driven pestle for 20 minutes 
on ice. The ratio of eggs to buffer is 50,000 eggs to 1 ml of LB.  Eggshells and cellular debris 
were removed with ultracentrifugation at 50,000 XG at 4°C for 60 minutes. The supernatant was 
collected, and stored at -80°C until use. Protein determinations were performed prior to 
performing IEF (Nezlin). 
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Rehydration of IPG Strips 4-10  
 For this procedure a solution of 40 microliters of SEA (80 – 100 µg), 150 microliters of 
Rehydration Buffer (2M thiourea, 7M urea, 2% IPG buffer 3-10, 2% DTT, 4% (w/v) CHAPS), 
and 5 microliters of Ampholytes 3-10 was used per IPG strip. The volume of the solution adds 
up to 195 microliters per strip. The strips were inserted into the rehydration tray positive end 
first. Then each solution was spread through its individual lane of the rehydration tray along the 
length of the strip, and care was taken to avoid creation of air bubbles in the lane to guarantee 
even hydration. The tray set overnight for processing (Nezlin). 
 
Isoelectric Focusing of IPG Strips 4-10 
The strips were inserted positive side towards the anode into the IPG cassette. 150 microliters of 
MQ water were added to two paper wicks, which touch both ends of the gel strips to ensure 
current flow. The anodic and cathodic electrodes were then attached to the paper wicks. The 
strips were isoelectric focused at 1000 V for one hour. Isolectric focusing sorts the proteins based 
on their pI (Nezlin). 
 
FIG. 5: Proteins are sorted by pI independent of size via isoelectric focusing. (“2-D Electrophoresis for Proteomics”)  
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Equilibration of IPG Strips 4-10 
Performing the equilibration procedure reduces and alkylates the proteins in the strips. By 
reducing, the double bonds in the protein are broken, and the globular protein becomes a linear 
protein. Alkylation treats the double bonds to ensure they will not reform later in the procedure. 
For this procedure, the strips were incubated in 5-15 mL of the Reducing Solution (5 mL 
ofequilibration buffer, 0.1 g of 1% dithiothreitol for two strips) for fifteen minutes at room 
temperature, and then they were incubated in 5-15 mL of the Alkylating Solution (5 mL of 
equilibration buffer, 0.125 g of 2.5% iodoacetaminde for two strips) for fifteen minutes at room 
temperature. The strips were then immediately set up to perform the two dimensional 
electrophoresis as detailed below (Nezlin).  
 
Two-Dimensional Electrophoresis 
For this procedure, NuPAGE Novex 4-12% Bis-Tris ZOOM Gels were used in addition to an 
IPG Well of 1.0 mm. 
Before beginning, the MOPS NuPage buffer was prepared with 40 mL MOPS and 760 mL MQ 
water. After preparing it, the comb was removed from the cassette, and the cassette was rinsed in 
MQ water. The equilibrated strip was then rinsed and trimmed, and it was inserted into the 
cassette such that the positive end faced towards the marker well. The MOPS NuPage buffer was 
poured over the strip to cover it. 5 mL of molecular weight marker was added to its respective 
well. Agarose sealing solution (100 mL Laemmli SDS electrophoresis buffer, 0.5g agarose, 200 
microliters1% Bromophenol blue stock solution) was added to cover the strip. The agarose 
solution stabilizes the strip so the proteins run into the polyacrylamide gel in a uniform fashion. 
After appropriately positioning the cassette, MOPS NuPAGE buffer was poured into the front, 
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center, and back electrophoresis chambers. Then 500 microliters of 2-Mercaptoethanol was 
added to the center chamber to act as an antioxidant in the procedure. The 2DE was performed at 
200 V for one hour, and then the gel was removed from the cast and set in fixer overnight.  
The next day, the gel was washed for ten minutes three times with MQ water. It was then stained 
with colloidal staining solution (170 g (NH4)2SO4, 340 mL CH3OH, 30 mL H3PO4) and set for 
an hour. After that, 100 microliters of 0.06% Coomassie G-250 (0.06 g Coomassie G-250 
dissolved in 100 mL MQ water) were added and the gel was set overnight to stain (Nezlin).   
 
Western Blot 
To properly perform the Immunoblot Western Blot technique, first nitrocellulose was moistened 
with distilled water that had been autoclaved to destroy indigenous phosphatases. Then the 
membranes were blocked for thirty minutes with the Blocking Solution, comprised of PBST (800 
mL distilled water, 8g NaCL, 0.2g KCl, and 5% Skim Milk. Skim milk is the blocking agent in 
the solution because it binds to any particles without proteins. The membranes were then washed 
with autoclaved water for five minutes before incubating in the primary antibodies (normal, 
MSS, and HSS) for one hour. The membranes were washed again for five minutes in autoclaved 
water before incubating in the secondary antibody (anti-mouse IgG) diluted 1:1,000 in PBST for 
one hour. Then the membranes were washed with PBST three times and with autoclaved water 
two times. Finally, they were incubated in Chromagen with rotation for one hour in order to 
cause any particles reacting with the IgG to turn black. The membranes were then washed one 
final time in autoclaved water and air-dried (Nezlin).   
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Protein Analysis 
In order to identify the resulting stained proteins from this experiment, the antigens must be 
compared to an SEA Proteomic map. The map used for this analysis was generated in The 
Center for Biodiscovery and Proteomics, University of Wellington, New Zealand. There, protein 
analysis was completed via Matrix-Assisted Laser Desorption/Ionization – Time of Flight 
(MADLI-TOF) mass spectrometry. The MALDI-TOF procedure results in peptide mass 
fingerprinting that allows for identification of each particular protein.  Once the proteins were 
recognized, they were identified on the National Center for Biotechnology Information (NCBI) 
protein database. 
 
FIG. 6: Protein Map of Schistosoma mansoni egg antigen (SEA): 2DE gel 4-12% Bis Tris, pl 3-10. Courtesy of The 
Center for Biodiscovery and Proteomics, University of Wellington, New Zealand. 
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CHAPTER III 
RESULTS 
 
The 2DE and Western blot procedures were repeated four separate times. The best of the results 
are included in this document for discussion. 
 
Results of Two-Dimensional Electrophoresis  
Illustrated below are the results of the stained 2DE of SEA pI 3-10.  
 
FIG. 7: SEA 2D gel pI 3-10, Coomassie blue stain, 4-12% Bis-Tris 
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Results of Western Blot Analysis 
The other three gels from the 2DE procedure were transferred to nitrocellulose for Western blot. 
Below are the results of the western blot analysis, with the gels incubated in the normal antibody, 
the MSS antibody, and the HSS antibody, respectively, in order to isolate the antigens only 
reacting to the specific types of antibodies.  
 
FIG. 8: Western blot of antibody-specific antigens: normal, MSS, and HSS, respectively.  
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Results of Protein Analysis 
  
FIG. 9: SEA unique to MSS and HSS as identified by Western Blot illustrated on 2DE gel of SEA  
By comparing the western blots of the different antibodies, it was possible to determine which 
SEA are unique to each type of antibody. As illustrated above, proteins 1, 2, and 3 are unique to 
MSS. Via the NCBI database, they have been identified as Calreticulin precursor, Calreticulin, 
and SJCHGCO1881 protein, respectively. Antigens 4 and 5 are unique to HSS. Antigen 5 has 
been identified as Enolase (2phosphoglycerate dehydratase), but the identity of antigen 4 is 
unknown. The genInfo identifier (gi) number of Calreticulin precursor and Calreticulin is 
1345835. The SJCHGCO1881 protein has a gi number of 56752775. Enolase’s gi number is 
3023710. 
MSS#
HSS#
1#
2#
3#
4#
5#
1.  Calre0culin#precursor#
2.  Calre0culin#
3.  SJCHGCO1881#protein#
4.  Unknown#
5.  Enolase#(2phosphoglycerate#dehydratase)#
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CHAPTER IV 
DISCUSSION 
The purpose of this research is to search for a more effective anti-pathology vaccine for 
schistosomiasis. Using the identified proteins from the MSS disease state in a vaccination 
should, in theory, promote down-regulation of the disease.  
To understand why this could occur, the documented characteristics of each protein should be 
examined. Using the UniProt database, this was possible. According to UniProt, Calreticulin and 
its precursor function in calcium binding that promotes healthy endoplasmic reticulum 
functioning (“Q06814 - CALR_SCHMA [Database record]”). The other protein of the MSS 
disease state, SJCHGCO1881, functions as a Phosphatase 2A inhibitor (“Q5DHV7 -
 Q5DHV7_SCHJA [Database record]”). Only one protein of the HSS disease state, Enolase, is 
documented, and it functions as a catalyst for the creation of phosphoenolpyruvate and water 
from 2-phospho-D-glycerate during glycolysis and carbohydrate digestion (“Q27877 -
 ENO_SCHMA” [Database record]). Future research would involve the effects of these proteins 
on the parasite’s functioning.  
Alternate interpretations of this data must be considered. Another possible outcome indicated by 
this data is that there could be an isotype difference between the MSS and HSS disease states, 
which could cause the different immune responses of down-regulation or inflammation, 
respectively. Another alternate interpretation to consider is that within the estimated thirty 
identical proteins found in both disease states, there could be an isotype to the same antigen 
recognized in both disease states that promotes a down-regulatory or inflammatory response. In 
order to confirm if unique antigens are responsible for the different immune responses, 
immunoprecipitation must be performed to isolate and concentrate the proteins in question 
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followed by further proteomic analysis. After that, trials to challenge CBJ/A mice with the 
antigens could begin to investigate whether the mice are protected against the inflammatory 
response after vaccination. 
Throughout the literature, a limited number of researchers have investigated the possibility of an 
anti-pathology vaccination for schistosomiasis. A study from 2002 investigated the possibility of 
using carbohydrate antigens in anti-pathology vaccines. The N-glycans investigated expressed 
LDN, LDNF, and polymeric Lewis x (Lex) [Galb1–4(Fuca1–3)GlcNAc]n-R epitopes. The 
researchers found that S. mansoni-infected patients primarily produced antibodies to LDN, 
LDNF, and Lex. However, the strongest immune responses resulted from exposure to LDN and 
LDNF (Nyame et al., 2003). Future studies could involve identifying these antigens in MSS and 
HSS and investigating the efficacy of the down-regulation effect of any N-glycans unique to 
MSS. Some researchers have considered the possibility of combining antigens in order to 
enhance effectiveness of antigen-based vaccinations. Researchers at Alexandria University in 
Alexandria, Egypt have investigated the combined effect of antigens Sm14 and Sm29 in mice 
infected with S. mansoni. The effect proved positive, with a “40.3%, 68.2%, and 57.9% 
reduction in adult worm burden, liver egg burden and intestinal eggs, respectively” (Ewaisha et 
al., 2014). Future tests could involve preparing vaccinations with combinations of the identified 
MSS and HSS antigens and other identified anti-pathogenic antigens, such as those mentioned 
above, to increase efficacy of a possible vaccine.  In a more recent study, published in August 
2014, Dr. Barbara C. Figueiredo et al. tested the potential of S. mansoni syntenin (SmSynt) as an 
antigen in an anti-pathology vaccine in hopes that it would hinder the growth and development 
of the parasite. This protein was investigated because it is especially present in the worm’s 
intravascular stage of life (the stage in which it infects humans), and it is involved in a variety of 
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essential functions related to protein scaffold support within the worm. It is also thought to be 
involved in the blood-feeding of the parasite. During the study, the research team immunized 
C57BL/6 mice with three doses of the vaccine formulated as 25 mg of histidine-tagged rSmSynt 
or as 25 mg of a PBS control. They found that the vaccinated group showed an increase in 
antibodies produced, reduced liver granuloma, and reduced adult worm burden as compared to 
the control. However, given that the reduction in adult worm burden was proportional to the 
reduction in female worm burden, the researchers believe that the vaccination did not affect the 
female’s ability to produce and release eggs. Because of the Th-1 immune response resulting 
from vaccination with SmSynt, the researchers suggest that the partial protection provided by the 
antigen could be combined with another antigen to create a more successful vaccine (Figueiredo 
et al., 2014). Combining SmSynt with an MSS antibody could potentially increase down-
regulation of the disease while simultaneously inhibiting cellular functions within the worm.  
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